Search results
Results from the WOW.Com Content Network
Late gadolinium enhancement (LGE) and T1 mapping allow infarction and fibrosis to be identified for characterizing cardiomyopathy and assessing viability. [8] Magnetic resonance angiography may be performed with or without contrast medium and is used to assess congenital or acquired abnormalities of the coronary arteries and great vessels. [9]
T 1-weighted images, left image without, right image with contrast medium administration. Gadolinium(III) containing MRI contrast agents (often termed simply "gado" or "gad") are the most commonly used for enhancement of vessels in MR angiography or for brain tumor enhancement associated with the degradation of the blood–brain barrier (BBB).
Delayed Gadolinium-enhanced MR Imaging of Articular Cartilage: Three-dimensional T1 Mapping with Variable Flip Angles and B1 Correction; Toward Imaging Biomarkers for Glycosaminoglycans; Longitudinal Evaluation of Cartilage Composition of Matrix-Associated Autologous Chondrocyte Transplants with 3-T Delayed Gadolinium-Enhanced MRI of Cartilage
The contrast agents used for DCE-MRI are often gadolinium based. Interaction with the gadolinium (Gd) contrast agent (commonly a gadolinium ion chelate) causes the relaxation time of water protons to decrease, and therefore images acquired after gadolinium injection display higher signal in T1-weighted images indicating the present of the agent.
Gadodiamide, sold under the brand name Omniscan, is a gadolinium-based MRI contrast agent (GBCA), used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels. Medical uses
The drug, under the brand name Dotarem, was brought to market by Guerbet. [13] It was launched on French market in 1989 and was FDA-approved in United States in March 2013. [13] As of 2013, gadoteric acid was approved in around 70 countries. [14] [15] Dotarem is the seventh FDA-approved GBCA for use in central nervous system MRI. [citation needed]
Gadobutrol-enhanced images were consistently favored over ProHance-enhanced images by all 3 blinded readers; Prior to approval for use in children under the age of 2 years old in 2015, a phase 1 clinical trial was conducted.
Gadopentetic acid, sold under the brand name Magnevist, is a gadolinium-based MRI contrast agent. [2]It is usually administered as a salt of a complex of gadolinium with DTPA (diethylenetriaminepentacetate) with the chemical formula A 2 [Gd(DTPA)(H 2 O)]; when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine".